AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9589926
Drug: Aspirin only
RxNorm normalized name: Aspirin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin only (group II, n = 49)
Trial: 8227340
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (IGF-I) 10 micrograms/kg.h
Trial: 31868008
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional analgesic treatment)
Trial: 26874683
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (CPT-Cognitive Only)
Trial: 25385727
Drug: Amrubicin 40
RxNorm normalized name: valrubicin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrubicin 40 mg/m² IV on days 1 to 3
Trial: 25385727
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m² IV on days 1 to 5
Trial: 20578378
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment at Shenshu (BL 23), Qihaishu (BL 24), Dachangshu (BL 25), and Pishu (BL 20) for 2 weeks
Trial: 20578378
Drug: Basic neurology
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic neurology therapies (Control group)
Trial: 16891991
Drug: Pamidronate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate infusion therapy
Trial: 10950398
Drug: Blinded study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blinded study drug alone
Trial: 10950398
Drug: Blinded drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded drug plus hydrochlorothiazide (HCTZ)
Trial: 10950398
Drug: Blinded drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded drugs plus HCTZ and additional drugs
Trial: 8978804
Drug: 5'-DFUR (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR (1,200 mg/day) administered preoperatively for 7 to 14 days
Trial: 3519193
Drug: Prophylactic endoscopic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic endoscopic paravariceal injection sclerotherapy (group IB)
Trial: 3519193
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (group IA)
Trial: 3519193
Drug: Prophylactic endoscopic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic endoscopic paravariceal injection sclerotherapy (group II)
Trial: 3519193
Drug: Regular monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular monitoring and re-injection (group II)
Trial: 15659494
Drug: DF (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DF (docetaxel 75 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Trial: 15659494
Drug: ECF (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)
Trial: 3181098
Drug: Riboflavin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (200 mg), retinol (15 mg), and zinc (50 mg) supplement
Trial: 11773179
Drug: Ranpirnase (Onconase;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranpirnase (Onconase; Alfacell Corp, Bloomfield, NJ), single weekly intravenous dose
Trial: 27438182
Drug: Aripiprazole addition
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole addition (adding aripiprazole to previous antipsychotics)
Trial: 27438182
Drug: Aripiprazole switching
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole switching (switching previous antipsychotics to aripiprazole)
Trial: 22507886
Drug: ω‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 fatty acids (1350 mg of eicosapentaenoic acid and 850 mg of docosahexaenoic acid daily)
Trial: 21409920
Drug: Brand 'A'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 'A' clopidogrel 600 mg
Trial: 21409920
Drug: Brand 'B'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand 'B' clopidogrel 600 mg
Trial: 17961722
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy followed by autologous transplantation of hematopoietic stem cells (HDT/ASCT)
Trial: 11950190
Drug: Oestrogen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen treatment (oestradiol valerate 2mg once daily)
Trial: 9585678
Drug: Clarithromycin group
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, clarithromycin 250 mg twice daily)
Trial: 9585678
Drug: Metronidazole group
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole group (amoxicillin 1000 mg twice daily, omeprazole 20 mg twice daily, metronidazole 500 mg twice daily)
Trial: 8607304
Drug: Topical tonsillar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tonsillar spray with 10% lidocaine 4 mg kg‐1 3 minutes before surgical incision
Trial: 8607304
Drug: Topical tonsillar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tonsillar spray with 10% lidocaine after both tonsils had been removed
Trial: 8607304
Drug: No topical
RxNorm normalized name: Altreno Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No topical spray (control group)
Trial: 8607304
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (both pre- and postoperative)
Trial: 2744908
Drug: Symmetric dosing
RxNorm normalized name: amantadine hydrochloride Oral Solution [Symmetrel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symmetric dosing with sustained-release theophylline (450 mg b.i.d.)
Trial: 2744908
Drug: Asymmetric dosing
RxNorm normalized name: An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymmetric dosing with sustained-release theophylline (270 mg plus 630 mg)
Trial: 6125195
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg pindolol
Trial: 31831564
Drug: Selinexor (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (60 mg oral) with Gemcitabine (1,000 mg/m2 i.v.) and Nab-Paclitaxel (125 mg/m2 i.v.)
Trial: 31831564
Drug: Selinexor-GEM-nab-paclitaxel combination
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Selinexor-GEM-nab-paclitaxel combination
Trial: 23455386
Drug: Arthroscopy-guided suprascapular
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopy-guided suprascapular nerve block using 10 mL 0.5 % ropivacaine with 1:200,000 epinephrine
Trial: 23455386
Drug: Placebo using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo using 10 mL 0.9 % saline
Trial: 21725239
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg) and Control
Trial: 16469019
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg CR oxybutynin
Trial: 16469019
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg CR oxybutynin
Trial: 16469019
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg CR oxybutynin
Trial: 15117983
Drug: CMF-->DOX (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF-->DOX (four courses of full-dose DOX followed by eight courses of i.v. CMF)
Trial: 9429741
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (MK-0476), 10 mg d-1 for 7 days
Trial: 9429741
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (MK-0476), 7 mg intravenous (5 min infusion)
Trial: 9429741
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (MK-0476), 10 mg oral dose
Trial: 8381624
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) 10 mg
Trial: 8381624
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NED) 10 mg
Trial: 27450091
Drug: Whole-flock treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-flock treatment with tilmicosin and enhanced biosecurity
Trial: 21029674
Drug: Alprostadil injection
RxNorm normalized name: alprostadil Injection
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil injection (10 µg i.v. once every 12 hours for 7 days)
Trial: 21029674
Drug: Alprostadil injection
RxNorm normalized name: alprostadil Injection
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprostadil injection
Trial: 15797147
Drug: Nurse administered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse administered intervention
Trial: 10489912
Drug: Pancrelipase capsules
RxNorm normalized name: Pancrelipase Capsules
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrelipase capsules
Trial: 1835661
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion 5‐fluorouracil plus cisplatin
Trial: 1835661
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methotrexate plus 5‐fluorouracil plus adriamycin (FAMTX)
Trial: 7034916
Drug: Bumetanide, 2
RxNorm normalized name: Bumetanide, 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide, 2 to 6 mg/d
Trial: 7034916
Drug: Furosemide, 40
RxNorm normalized name: Furosemide, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide, 40 to 160 mg/d
Trial: 24876430
Drug: Test Meter
RxNorm normalized name: prothrombin time/INR test meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Meter with in-built insulin calculator
Trial: 24876430
Drug: Usual method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual method of testing blood glucose and deciding insulin doses
Trial: 22577270
Drug: Probiotic complex
RxNorm normalized name: RITE AID Probiotic Complex Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic complex containing B. bifidum, L. acidophilus, L. casei, and L. salivarius for 8 weeks
Trial: 19229814
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus renal artery stenting (angioplasty group)
Trial: 19229814
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (drug therapy group)
Trial: 15064916
Drug: Olanzapine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-10 mg/day, once or twice daily)
Trial: 15064916
Drug: Fluphenazine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine (5-10 mg/day, once or twice daily)
Trial: 11870677
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg tablet (test formulation)
Trial: 11870677
Drug: Norvasc 5
RxNorm normalized name: Norvasc 5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norvasc 5 mg tablet (reference formulation)
Trial: 8170179
Drug: Primary coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary coronary angioplasty without prior thrombolytic therapy
Trial: 8170179
Drug: Immediate adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate adjunctive angioplasty after thrombolytic therapy
Trial: 8170179
Drug: Rescue angioplasty
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue angioplasty after failed thrombolytic therapy
Trial: 8170179
Drug: Deferred adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred adjunctive angioplasty during the weeks after infarction
Trial: 3342656
Drug: MDI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI with InspirEase (3 puffs of metaproterenol 0.65 mg/puff) plus nebulizer with placebo
Trial: 3342656
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI with InspirEase plus nebulizer with 15 mg metaproterenol
Trial: 2041147
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg OFLX (twice daily)
Trial: 2041147
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg OFLX (twice daily)
Trial: 2041147
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg OFLX (twice daily)
Trial: 2041147
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg OFLX (twice daily)
Trial: 25989270
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus pimasertib (45 mg/day)
Trial: 25989270
Drug: FOLFIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI plus pimasertib (60 mg/day)
Trial: 11580742
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with six monthly depot injections of leuprolide acetate (LA)
Trial: 11580742
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment with two monthly LA injections
Trial: 3107601
Drug: Nalbuphine 20
RxNorm normalized name: nalbuphine 20 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 20 mg i.v.
Trial: 19379147
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic agents (OHAs)
Trial: 29395308
Drug: Collagen-fibrin patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-fibrin patch
Trial: 25928620
Drug: Adaptive servo-ventilation
RxNorm normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adaptive servo-ventilation (ASV) therapy for 24 weeks along with guideline-directed medical therapy
Trial: 25928620
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy for 24 weeks
Trial: 8561762
Drug: Fear of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fear of flying and fear of injections as a function of age in women
Trial: 6337491
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of Cefoxitin
Trial: 25030722
Drug: Pregabalin and
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin and nonsteroidal anti-inflammatory drug combination therapy
Trial: 25030722
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug monotherapy
Trial: 23165739
Drug: 5‐HT (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HT (50 µg)
Trial: 23165739
Drug: Histamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine (0.2 µg)
Trial: 12875586
Drug: Phenoxybenzamine (alpha-sympathetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine (alpha-sympathetic blocking agent) applied to nasal mucosa
Trial: 10442799
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg, n = 184)
Trial: 10442799
Drug: Amitriptyline (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50-100 mg, n = 191)
Trial: 7790289
Drug: Program L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program L (low stimulation)
Trial: 467482
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN), 5 mg, sublingually
Trial: 467482
Drug: Nifedipine (N),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (N), 10 mg, orally
Trial: 467482
Drug: Verapamil (V),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (V), 160 mg, orally
Trial: 467482
Drug: Propranolol (Pr),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (Pr), 40 mg, orally
Trial: 21871667
Drug: Short-Term Therapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-Term Therapy
Trial: 19356391
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1200 mg once daily for 6 days
Trial: 19356391
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride 850 mg single-dose
Trial: 18193500
Drug: Poly-L-lactic acid
RxNorm normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-L-lactic acid (PLA) injections administered every 2 weeks for 4 treatments
Trial: 18193500
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (deferred PLA treatment)
Trial: 9747746
Drug: Intravenous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous IL-2 (9 Mio I.U. per day)
Trial: 9747746
Drug: Subcutaneous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL-2 (9 Mio I.U. per day)
Trial: 9747746
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Intravenous and Subcutaneous IL-2)
Trial: 8878381
Drug: FK506 (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 (low trough level 5-14 ng/ml)
Trial: 8878381
Drug: FK506 (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 (medium trough level 15-25 ng/ml)
Trial: 8878381
Drug: FK506 (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK506 (high trough level 26-40 ng/ml)
Trial: 2265113
Drug: hM-CSF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hM-CSF (2 x 10(5) units/kg daily from day 1 to day 14 after BMT)
Trial: 29773947
Drug: BFF MDI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BFF MDI 320/9.6 μg
Trial: 28635557
Drug: Intradermal split-virus
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal split-virus TIV
Trial: 25668581
Drug: Erhuangfang (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erhuangfang (treatment group, n=50)
Trial: 16651569
Drug: Periarticular intraoperative
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular intraoperative injection containing ropivacaine, ketorolac, epimorphine, and epinephrine
Trial: 8949810
Drug: Droperidol added
RxNorm normalized name: Droperidol
DrugBank: Droperidol (DB00450)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Droperidol added to morphine infusion
Trial: 6784982
Drug: Naloxone (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (long-term infusion)
Trial: 6784982
Drug: High-dose DAMME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DAMME infusion
Trial: 28903864
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate and vilanterol (100 μg or 200 μg with 25 μg vilanterol)
Trial: 19410392
Drug: DHEA 50mg
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
DrugBank: Prasterone sulfate (DB05804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50mg daily
Trial: 9508013
Drug: Milk diet
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk diet (360 mL)
Trial: 9508013
Drug: Juice diet
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Juice diet (540 mL)